Journal
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
Volume 13, Issue 6, Pages 623-629Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ACI.0000000000000013
Keywords
immunoglobulin; patient education; primary immune deficiency; self-infusion; subcutaneous
Categories
Funding
- NIHR Oxford Biomedical Research Centre
- EU
- Primary Immunodeficiency Association
- Jeffrey Modell Foundation
- Baxter Healthcare
- Biotest
- LFB
- Karolinska Institutet, Stockholm, Sweden
Ask authors/readers for more resources
Purpose of reviewRapid subcutaneous immunoglobulin (SCIg) infusions have been used as an important method of delivering replacement immunoglobulin (Ig) to patients with primary immune deficiencies (PIDs) in Europe over the last 25 years. This review provides a comprehensive interpretation of the literature relating to the administration of SCIg and the services that have been developed alongside.Recent findingsUsing rates of at least 20ml/h per infusion site and simultaneous sites, the infusion time once per week is short (1-2h in adults) and using small portable pumps, the child or adult is free for other activities during the therapy. The rapid SCIg infusions have been documented as well tolerated, efficacious and acceptable to infants and their parents, children, adults and elderly patients, and more recently to patients with autoimmunity requiring immunomodulatory Ig doses.SummaryAs part of PID diagnostic and management services, educational programmes for self-infusion of both intravenous Ig and SCIg at home have been developed throughout Europe, resulting in increased patient compliance and patient empowerment as well as cost-savings for healthcare providers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available